TY - JOUR
T1 - Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents
AU - Natelson, Ethan A.
AU - Giovanella, Beppino C.
AU - Verschraegen, Claire F.
AU - Fehir, Kim M.
AU - De Ipolyi, Peter D.
AU - Harris, Nick
AU - Stehlin, John S.
PY - 1996
Y1 - 1996
N2 - Groups of 52 and 29 patients with refractory cancers received either native camptothecin (CPT) or 9-nitrocamptothecin (9NC), respectively, in Phase I clinical trials designed to determine the maximum tolerated dose, toxicity and potential efficacy of orally administered camptothecins. Favorable responses occurred with both compounds (11% after CPT, 24% after 9NC). Although both agents could be taken safely for extended periods, dose limiting toxicities were substantial. Diarrhea was the major clinical problem with CPT, and myelosuppression with 9NC. Both compounds could cause hemorrhagic cystitis. The antitumor activity demonstrated suggests that further investigation of orally administered camptothecin analogs is warranted.
AB - Groups of 52 and 29 patients with refractory cancers received either native camptothecin (CPT) or 9-nitrocamptothecin (9NC), respectively, in Phase I clinical trials designed to determine the maximum tolerated dose, toxicity and potential efficacy of orally administered camptothecins. Favorable responses occurred with both compounds (11% after CPT, 24% after 9NC). Although both agents could be taken safely for extended periods, dose limiting toxicities were substantial. Diarrhea was the major clinical problem with CPT, and myelosuppression with 9NC. Both compounds could cause hemorrhagic cystitis. The antitumor activity demonstrated suggests that further investigation of orally administered camptothecin analogs is warranted.
UR - http://www.scopus.com/inward/record.url?scp=0030453707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030453707&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.1996.tb26392.x
DO - 10.1111/j.1749-6632.1996.tb26392.x
M3 - Article
C2 - 8993516
AN - SCOPUS:0030453707
SN - 0077-8923
VL - 803
SP - 224
EP - 230
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
ER -